Company Encyclopedia
View More
name
eDiagnosis
002932.SZ
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware products.
876.46 B
002932.SZMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking44/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE0.12%D
    • Profit Margin2.02%C
    • Gross Margin18.90%D
  • Growth ScoreD
    • Revenue YoY0.58%C
    • Net Profit YoY-32.82%D
    • Total Assets YoY-10.67%E
    • Net Assets YoY-6.27%D
  • Cash ScoreB
    • Cash Flow Margin4949.46%A
    • OCF YoY0.58%C
  • Operating ScoreE
    • Turnover0.05E
  • Debt ScoreA
    • Gearing Ratio6.13%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    eDiagnosis released its performance for the first three quarters, with a net profit attributable to the parent company of 13.5155 million yuan, a decrease of 83.30%

    According to the Zhitong Finance APP, eDiagnosis released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 227 million yuan, a year-on-year increase of 0.53%. The net profit attributable to shareholders of the listed company was 13.5155 million yuan, a year-on-year decrease of 83.30%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 63.3294 million yuan. The basic earnings per share were 0.0616 yuan

    Zhitong·
    SZ
    002932
    -0.39%
    Zhitong·
    SZ
    002932
    -0.39%

    eDiagnosis released its performance for the first half of the year, with a net profit attributable to the parent company of 12.4973 million yuan, a year-on-year decrease of 80.82%

    eDiagnosis released its 2025 semi-annual report, with operating revenue of 139 million yuan, a year-on-year decrease of 9.71%; net profit attributable to the parent company was 12.4973 million yuan, a year-on-year decrease of 80.82%. After deducting non-recurring gains and losses, the net loss was 35.6218 million yuan, a year-on-year loss increase of 23.59%. Basic earnings per share were 0.06 yuan

    Zhitong·
    SZ
    002932
    -0.39%
    Zhitong·
    SZ
    002932
    -0.39%

    eDiagnosis releases nucleic acid testing solutions for Chikungunya virus and mosquito-borne pathogens

    Recently, eDiagnosis released a nucleic acid testing solution for Chikungunya virus and mosquito-borne pathogens. For Chikungunya fever, test results can be generated in as fast as 1 hour. "We use fluorescent PCR methods, with a sensitivity of 50-200 copies/mL. In other words, even if there are only a few viral particles in 1 mL of blood, they can be detected," said a relevant person in charge at eDiagnosis. This solution has been implemented in disease control centers and hospitals in Hubei Province and the southwestern region of China

    Zhitong·
    SZ
    002932
    -0.39%
    Zhitong·
    SZ
    002932
    -0.39%

    eDiagnosis launches nucleic acid testing solutions for Chikungunya virus and mosquito-borne pathogens

    According to eDiagnosis, in response to the demand for "early screening and early control" in the prevention and control of Chikungunya fever, eDiagnosis has launched a nucleic acid testing solution for Chikungunya virus and mosquito-borne pathogens, providing efficient and rapid testing capabilities to strengthen the epidemic monitoring defense line

    Zhitong·
    SZ
    002932
    -0.39%
    Zhitong·
    SZ
    002932
    -0.39%

    eDiagnosis Investment establishes a new company including biobased materials business

    According to the Qichacha APP, recently, Dongguan Mingzhi Lechong Technology Co., Ltd. was established, with Ye Changqin as the legal representative. The business scope includes: research and application of cell technology; manufacturing of bio-based materials; research and development of industrial enzyme preparations; manufacturing of smart home consumer devices, etc. Qichacha's equity penetration shows that the company is wholly owned by Guangdong Mingzhi Medical Laboratory Co., Ltd., a subsidiary of eDiagnosis

    Zhitong·
    SZ
    002932
    -0.39%
    Zhitong·
    SZ
    002932
    -0.39%
    © 2025 Longbridge｜Disclaimer